Physics and radiobio written</h1> <article> <h1>Physics and radiobio written</h1> <p>bahari-kashani — Fri, 27 Aug 2010 19:31:10 GMT</p> <p>As I recall, the physics and radiobio boards are on a Thursday. I took off Mon, Tues, and Wed to study. I probably began studying in earnest 6 weeks before that. I am sure that I could have gone over the material another couple of times, done some recalls, more RAPHEXs, etc. if I took more time off, but I did just fine on the exam itself, which I found to be very fair (not easy, but fair).</p><div style="clear:both;"></div> </article> <article> <h1>6th International IMRT Symposium: Target Delineation and Safety Measure Radaition Oncology Symposium and Workshop</h1> <p>Tony Wang — Wed, 25 Aug 2010 15:13:35 GMT</p> <p>Overview:</p> <p>IMRT is the treatment of choice for many cancers. This therapy requires rigorous attention to planning and delivery to ensure the safety and efficacy of the technology. Participants at the 6th International IMRT Symposium will be provided the most current guidelines, safety measures and QA processes, along with disease-specific planning tools. Proper planning, positioning, and dosage application will ensure patient safety achievement of expected outcomes.</p> <p>Interactive Breakout Sessions:</p> <p>Attendees may choose one of three interactive breakout sessions that discuss real-world cases and demonstrate treatment planning on IMRT systems.</p> <p>Physician Course Directors:</p> <p>K.S. Clifford Chao, M.D.</p> <p>Nancy Lee, M.D.</p> <p>Date and Time:</p> <p>Monday, September 20, 2010 7:15am-6:20pm (7:15 -7:45am Registration/Continental Breakfast)</p> <p>Location:</p> <p>The Goldstein Education & Conference Center and Daniels Auditorium</p> <p>177 Fort Washington Avenue at West 165th Street</p> <p>New York, NY, USA</p> <p>To Register:</p> <p>Register ONLINE at: <a href="http://www.nyp.org/radiationoncology">www.nyp.org/radiationoncology</a></p><div style="clear:both;"></div> </article> <article> <h1>Job Application</h1> <p>Tony Wang — Thu, 19 Aug 2010 15:02:42 GMT</p> <p>Posted anonymously:</p> <p>Academic or Private Practice: Private</p> <p>How did you find your job (i.e. web forum, word of mouth, etc?): email-word of mouth</p> <p>Number of job interviews: 20</p> <p>General advice: apply early and often. Take time to make your decision and seek out people who have worked for or with your future partners for advice about the job. Get a lawyer and make sure that you are protected. If their lawyer won't make changes that your lawyer says are standard, then reject the contract and take another job.</p> <p> </p> <p>Posted anonymously:</p> <p>Academic or Private Practice: Looking at both</p> <p>How did you find your job (i.e. web forum, word of mouth, etc?): NA, just starting my pGY5 year</p> <p>Number of job interviews: NA, just starting my PGY5 year</p> <p>General advice: NA, just starting my PGY-5 year.</p><div style="clear:both;"></div> </article> <article> <h1>2011 Seattle Prostate Brachytherapy Fellowship</h1> <p>Tony Wang — Thu, 19 Aug 2010 14:46:35 GMT</p> <p>We invite you to apply for the Seattle Prostate Brachytherapy Fellowship, sponsored by the American Brachytherapy Society and generously funded by Oncura. This fellowship provides residents with the exposure to prostate brachytherapy and the unique opportunity to work closely with some of the world experts and pioneers in the field.</p> <p>Fellowship recipients will spend one to two weeks in Seattle during which time they will visit Seattle Prostate Institute, Seattle Veterans Administration, the Prostate Cancer Treatment Center, and the Group Health Cooperative. Faculty will include Stephen Eulau, M.D., Peter Grimm, D.O., John Sylvester, M.D., Robert Takamiya, M.D., and Kent Wallner, M.D. A stipend of $1,000 will be awarded to residents at the conclusion of the fellowship. Fellowship recipients will be recognized in the ABS newsletter and at the 2011 annual ABS meeting.</p> <p>Residents of accredited domestic radiation oncology programs are eligible to apply. We ask that all applicants sign up for ABS membership (membership dues are waived for members-in-training).</p> <p>Applications: Available online at the ABS website-- <a href="http://www.americanbrachytherapy.org">www.americanbrachytherapy.org</a></p> <p>Deadline: December 7, 2010</p><div style="clear:both;"></div> </article> <article> <h1>Baylor College of Medicine Residency Opening</h1> <p>jhaveri77030 — Tue, 17 Aug 2010 18:50:06 GMT</p> <p> </p> Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 <p> </p> <h4>Baylor College of Medicine in Houston, TX has an immediate opening for a residency position (PGY-4 preferred but PGY2 and PGY-3 will also be considered) beginning January 1, 2011 or earlier.<br /><br />The radiation oncology residency program is fully ACGME-accredited and in good standing. Our department has excellent clinical and academic training with a strong presence in the Texas Medical Center. Residents have extensive experience with all major treatment techniques including IMRT, IGRT, CyberKnife and others. Formal prostate brachytherapy training at MD Anderson is an integral part of the program. <br /><br />A wide variety of patients and disease types are seen through rotations at St. Luke’s Episcopal Hospital, Ben Taub General Hospital, The Houston VA Hospital, M.D. Anderson, and Texas Children’s Hospital/Methodist Hospital.<br /><br />Please reply to the program director – Steve Carpenter, MD (scarpenter@sleh.com) and the chief resident – Snehal Desai, MD (ssdesai@bcm.edu) with your current CV. Interviews will be held shortly.</h4> <p class="MsoNormal"><span style="font-size:10pt;line-height:115%;font-family:'Verdana','sans-serif';"></span></p> <p> <span style="font-size:12pt;line-height:115%;font-family:'Arial Narrow','sans-serif';"></span></p><div style="clear:both;"></div> </article> <article> <h1>Opening for PGY-2 resident position at UC-Irvine</h1> <p>bahari-kashani — Wed, 04 Aug 2010 23:28:57 GMT</p> <p class="MsoNormal" style="margin:0in 0in 0pt;"><span style="font-family:Times New Roman;font-size:small;">The University of California (Irvine) Residency Program in Radiation Oncology is an integrated program consisting of the University of California, Irvine, Medical Center, the Veterans Affairs Medical Center, Long Beach, and Memorial Medical Center of Long Beach. </span></p> <p class="MsoNormal" style="margin:0in 0in 0pt;"><span style="font-family:Times New Roman;font-size:small;"> </span></p> <p class="MsoNormal" style="margin:0in 0in 0pt;"><span style="font-family:Times New Roman;font-size:small;">One radiation oncology residency position is available at the PGY-2 level to begin in 2010 or 2011. Interviews will likely begin August 2010 and are expected to be completed prior to the start of the regular 2011 ERAS/NRMP recruitment cycle. The Program is sponsored by the University of California, Irvine. As an integrated program, residency training is conducted at the University of California, Irvine Medical Center, Veterans Affairs Medical Center, and Long Beach, Memorial Medical Center of Long Beach. The Residency in Radiation Oncology is designed to prepare physicians for successful careers in clinical and scientific radiation oncology. The program of study is also designed to meet the requirements of the Radiation Oncology section of the American Board of Radiology’s specialty examination. </span></p> <p class="MsoNormal" style="margin:0in 0in 0pt;"><span style="font-family:Times New Roman;font-size:small;"> </span></p> <p class="MsoNormal" style="margin:0in 0in 0pt;"><span style="font-family:Times New Roman;font-size:small;"> </span></p> <p class="MsoNormal" style="margin:0in 0in 0pt;"><span style="font-family:Times New Roman;font-size:small;">The Program offers a four year training program in Radiation Oncology following the successful completion of a preliminary training year with at least 9 months of patient care. Applicants will also be expect to fulfill the general criteria set forth for residents by the University of California, Irvine School of Medicine. For the latest update on residency accreditation (by the ACGME), interested parties are invited to inquire with the Program Director. </span></p> <p class="MsoNormal" style="margin:0in 0in 0pt;"><span style="font-family:Times New Roman;font-size:small;"> </span></p> <p class="MsoNormal" style="margin:0in 0in 0pt;"><span style="font-family:Times New Roman;font-size:small;">How to apply: The residency program is accredited for 5 positions. At present, our intention is to recruit for only 1 of our 2 unfilled positions to begin 2010 or 2011, which will bring the total number of residents to 4. For more information on how to apply, e-mail the Program Director. Email correspondence should be addressed to the Program Director, Attention: Residency Recruitment at jvkuo@uci.edu. If you have any questions, please call us (714) 456-8074 and ask either for the Residency Coordinator Ms. Alice Oduca or the Program Director, Dr. Kuo.</span></p> <p class="MsoNormal" style="margin:0in 0in 0pt;"><span style="font-family:Times New Roman;font-size:small;"> </span></p> <p class="MsoNormal" style="margin:0in 0in 0pt;"><span style="font-family:Times New Roman;font-size:small;"> </span></p> <p class="MsoNormal" style="margin:0in 0in 0pt;"><span style="font-family:Times New Roman;font-size:small;"> </span></p> <p class="MsoNormal" style="margin:0in 0in 0pt;"><span style="font-family:Times New Roman;font-size:small;">For more information, please visit our website: http://www.ucihs.uci.edu/radonc/education.html</span></p><div style="clear:both;"></div> </article> <article> <h1>UFPTI Proton Fellowship Opening</h1> <p>Tony Wang — Thu, 29 Jul 2010 17:07:01 GMT</p> <p style="padding-left:30px;">The University of Florida Proton Therapy Insitute (UFPTI) is excited to announce two new fellowships in proton therapy. One position will focus on pediatric proton therapy while the other will involve proton therapy for adult patients. This will be a 12-month program which can be renewed for one more year with mutual consensus of the program and the fellow. Both fellowships will center on developing clinical expertise in proton therapy, with the opportunity to engage in research. It is expected the fellow will pursue at least one project in clinical, translational or laboratory research. The primary clinical training will focus on the application of proton therapy to treat malignant tumors. In pediatrics, this will include primary central nervous system tumors, sarcomas, and other solid tumors adjacent to critical radiosensitive organs. In adults, prostate cancern, lung cancer, gastrointestinal malignancies, head and neck malignancies and central nervous system tumors will be the focus, and the experience in rare tumors particularly suited for protons also expected. Management of benign unresectable tumors of the central nervous system will be addressed in both the pediatric and adult patients. In addition to 3 proton gantries and a fixed beam, the University of Florida Proton Institute houses state of the art linear accelerators for IMRT, IGRT, and photon radiosurgery. The fellowship will include instruction on when these tools may be utilized in a way that complements proton therapy. The University of Florida Proton Institute is one of the busiest proton centers in the world and treats over 100 patients daily with a broad range of diagnoses. Active research includes over a dozen institutional clinical trials as well as cooperative trials with COG, POETIC, and St. Jude Children's Research Hospital. This provides a unique opportunity to develop clinical skills in a growing and novel high-technology field. We welcome applications for these positions.</p> <ul style="padding-left:30px;"> <li>The fellowship directors are Robert B. Marcus, Jr, M.D.: <a href="mailto:rmarcus@floridaproton.org">rmarcus@floridaproton.org</a> and Daniel Indelicato, M.D.: <a href="mailto:dindelicato@floridaproton.org">dindelicato@floridaproton.org</a></li> <li>The fellow will be formally appointed as a Clinical Instructor in the University of Florida College of Medicine with commensurate salary and benefits.</li> <li>Although not absolutely required, it is recommended that the fellow successfully complete an ACGME accredited residency in Radiation Oncology by the start date of the fellowship. Starting date is negotiable. All applications to start on January 1, 2011 must be received by October 1st, 2010. All applications to start on July 1, 2011 must be received by May 1st, 2011. If a fellow wishes to be considered to start at a time other than those listed, please contact one of the fellowship directors.</li> <li>Qualified international applicants will be considered.</li> <li>The application must include a current Curriculum Vitae and a one page personal statement articulating the candidate's interest in one of the fellowships. The personal statement should clearly state whether the applicant wishes to pursue a pediatric or an adult fellowship. Three letters of recommendation from clinical and/or research mentors are also required, including one from the fellow's residency director.</li> <li>Please e-mail CV and personal statement to Ms. Renee Barber: <a href="mailto:rbarber@floridaproton.org">rbarber@floridaproton.org</a> and have letters of recommendation sent to:</li> </ul> <p style="padding-left:30px;">Renee Barber</p> <p style="padding-left:30px;">University of Florida Proton Therapy Institute</p> <p style="padding-left:30px;">2015 N. Jefferson Street</p> <p style="padding-left:30px;">Jacksonville, FL 32206</p><div style="clear:both;"></div> </article> <article> <h1>ACR In-service Examination Information</h1> <p>ARRO — Thu, 12 Nov 2009 21:29:35 GMT</p> <p><a href="http://rfs.acr.org/#/Exams">ACR In-service Examination Information</a></p><div style="clear:both;"></div> </article> <article> <h1>Emory University Residency Postion Opening (revised)</h1> <p>Jay Shelton — Tue, 08 Jun 2010 14:02:58 GMT</p> <p style="margin:0in 0in 0pt;mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;" class="MsoNormal"><span style="font-size:small;"><span style="font-family:Times New Roman;"><span style="text-decoration:underline;"><span style="color:black;">Radiation Oncology Residency Opening</span></span><span style="color:black;">:</span></span></span></p> <p><span style="font-size:10pt;color:black;font-family:'Tahoma','sans-serif';mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA;">Emory University (Atlanta, GA) has an immediate opening for residency position (PGY-3 preferred but PGY2 through PGY 4 will be considered) beginning July 1, 2010. Our radiation oncology residency program is fully ACGME-accredited and in good standing. Our department has outstanding academic resources in clinical radiation oncology, radiobiology, & physics as well as a strong position within a major cancer center. Please reply to either the program coordinator – Patrice Moua at 404-778-4763 or <a href="mailto:pmoua@emory.edu"><span style="color:#0048c0;">pmoua@emory.edu</span></a> or the program director – Dr. Ashesh B. Jani at <a href="mailto:abjani@emory.edu"><span style="color:#0048c0;">abjani@emory.edu</span></a> with your current CV/reference list. Interviews will be held very shortly (mid- to late June).</span></p><div style="clear:both;"></div> </article> <article> <h1>Emory University PGY-3 Opening</h1> <p>Jay Shelton — Thu, 03 Jun 2010 02:45:12 GMT</p> <p> <p class="MsoNormal">Emory University (Atlanta, GA) has an immediate opening for a PGY-3 position beginning July 1, 2010. Please reply to either the program coordinator – Patrice Moua at 404-778-4763 or <a href="mailto:pmoua@emory.edu">pmoua@emory.edu</a> or the program director – Dr. Ashesh B. Jani at <a href="mailto:abjani@emory.edu">abjani@emory.edu</a> with your current CV (including reference list). Interviews will be held very shortly (mid- to late June 2010). </p> </p><div style="clear:both;"></div> </article> <article> <h1>PGY-2 Opening at University of Cincinnati for 7/2010</h1> <p>Shannon — Wed, 26 May 2010 15:38:32 GMT</p> <p>There is a PGY-2 opening at the University of Cincinnati to start 7/1/10. <br /> <br /> Please contact the program director, <br /> <br /> <b>Ruth Lavigne, MD</b> at <a href="mailto:ruth.lavigne@healthall.com">ruth.lavigne@healthall.com</a><br /> <br /> or the program coordinator, <br /> <br /> <b>Mary Kay Rehard</b> at <a href="mailto:mary.rehard@healthall.com">mary.rehard@healthall.com</a> or 513-584-9089<br /> <br /> for further information. <br /> <br /> You can also feel free to contact me, the chief resident <br /> <br /> <b>Shannon Offerman</b> at <a href="mailto:offermsn@ucmail.uc.edu">offermsn@ucmail.uc.edu</a><br /> <br /> You will need to submit a CV, personal statement, letters of recommendation and USMLE scores. </p><div style="clear:both;"></div> </article> <article> <h1>ACRO Resident Committee Application</h1> <p>Shane Hopkins — Mon, 24 May 2010 15:57:35 GMT</p> <p>The ACRO Resident Committee is a group of resident leaders organized by the American College of Radiation Oncology's Board of Chancellors. The committee has open positions and is accepting applications, due June 1. Get more information and download the application at <a href="http://acro.org/residents/tiki-index.php">http://acro.org/residents/tiki-index.php</a></p><div style="clear:both;"></div> </article> <article> <h1>PGY-2 opening at the University of Cincinnati to start 7/1/10</h1> <p>Shannon — Fri, 21 May 2010 14:50:10 GMT</p> <p>There is a PGY-2 opening at the University of Cincinnati to start 7/1/10. <br /> <br /> Please contact the program director, <br /> <br /> <b>Ruth Lavigne, MD</b> at <a href="mailto:ruth.lavigne@healthall.com">ruth.lavigne@healthall.com</a><br /> <br /> or the program coordinator, <br /> <br /> <b>Mary Kay Rehard</b> at <a href="mailto:mary.rehard@healthall.com">mary.rehard@healthall.com</a> or 513-584-9089<br /> <br /> for further information. <br /> <br /> You can also feel free to contact me, the chief resident <br /> <br /> <b>Shannon Offerman</b> at <a href="mailto:offermsn@ucmail.uc.edu">offermsn@ucmail.uc.edu</a><br /> <br /> You will need to submit a CV, personal statement, letters of recommendation and USMLE scores.<br /></p><div style="clear:both;"></div> </article> <article> <h1>General Textbooks</h1> <p>ARRO — Thu, 12 Nov 2009 19:29:29 GMT</p> <p><span style="text-decoration:underline;"><b>AJCC Cancer Staging Manual</b></span>. Lippincott Williams and Wilkins. 6th Edition (2002; 7th edition scheduled for publication in 2009) <span style="text-decoration:underline;"></span></p> <p><b><span style="text-decoration:underline;">Handbook of Evidence-Based Radiation Oncology</span></b>. Eric Hansen and Mack Roach. Springer. 1st Edition (2006)</p> <p><b><span style="text-decoration:underline;">Handbook of Radiation Oncology: Basic Principles and Clinical Protocols</span></b>. Bruce Haffty and Lynn Wilson. Jones & Bartlett Publishers. 1st Edition (2008)</p> <p><b><span style="text-decoration:underline;">DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology</span></b>. Lippincott Williams and Wilkins. 8th Edition (2008) </p> <p><span style="text-decoration:underline;"><b>Clinical Radiation Oncology</b></span>. Leonard Gunderson and Joel Tepper. Churchill Livingstone. 2nd edition (2006)</p> <p><b><span style="text-decoration:underline;">Perez and Brady's Principles and Practice of Radiation Oncology</span></b>. Edward C Halperin, Carlos A Perez, Luther W Brady, David E Wazer, Carolyn Freeman, Lippincott Williams and Wilkins. 5th Edition (2007) </p> <p><span style="text-decoration:underline;"><b>Radiation Oncology: Rationale, Techniques, Results</b></span>. James Cox and Kian Ang. 8th Edition (2002)</p> <p><b><span style="text-decoration:underline;">Radiation Oncology-Management Decisions</span></b>. K. S. Clifford Chao, Carlos A Perez, Luther W Brady, Lippincott Williams and Wilkins. 2nd Edition (2001)</p> <p><span style="text-decoration:underline;"><b>Radiation Oncology for Cure and Palliation</b></span>. Robert Parker. Springer Verlag, Inc. 1st Edition (2003)</p> <p><span style="text-decoration:underline;"><b>Radiation Toxicity: A Practical Guide</b></span>. William Small and Gayle Woloschak, Springer. 1st Edition (2005)</p> <p><span style="text-decoration:underline;"><b>Textbook of Radiation Oncology</b></span>. Steven A Leibel. Saunders. 2nd Edition (2004) </p><div style="clear:both;"></div> </article> <article> <h1>PGY-2 Opening at University of Louisville to Start 7/1/2010</h1> <p>freemanab — Thu, 20 May 2010 12:19:13 GMT</p> <p>Pending approval in the next week, the University of Louisville will have a PGY-2 position available to start 7/1/2010 to all those eligible who have completed an accredited preliminary year. </p> <p>Any interested can contact the program coordinator listed below:</p> <p> </p> <p>Patty Walker</p> <p>pawalk01@gwise.louisville.edu</p> <p>502-561-2700</p> <p>or Chief Resident:</p> <p>Andy Freeman</p> <p>abfree03@louisville.edu</p><div style="clear:both;"></div> </article> <article> <h1>2010 ASTRO/ARRO Physics Core Curriculum</h1> <p>Tony Wang — Wed, 19 May 2010 19:27:10 GMT</p> <p>ASTRO's Committee on Physics Curriculum for Residents recently published 2010 updates to the Core Curriculum today, 5/18/10, onto the ARRO website. Some changes in curriculum include addition of Radiation Incidents and Bioterrorism Response Training and updates that reflect new treatment techniques and modalities.<br /> <br /> <a href="http://www.astro.org/ARRO/Certification/PhysicsRadBioCurriculum/index.aspx">http://www.astro.org/ARRO/Certification/PhysicsRadBioCurriculum/index.aspx</a></p><div style="clear:both;"></div> </article> <article> <h1>Stereotactic Radiosurgery Fellowship at the UPMC</h1> <p>ParikhS — Thu, 29 Apr 2010 12:16:29 GMT</p> <p style="margin:0in 0in 10pt;" class="MsoNormal"><span style="font-size:small;font-family:Calibri;">The University of Pittsburgh Cancer Institute (UPCI) is excited to announce a new fellowship in stereotactic radiosurgery and stereotactic body radiotherapy (SRS/SBRT).<span style="mso-spacerun:yes;"> </span>This 12-month program will integrate patient-centered clinical oncology with the opportunity to engage in cutting-edge research.<span style="mso-spacerun:yes;"> </span>The primary clinical training will be focused on the application of SRS/SBRT to treat malignant and benign tumors of the brain, base of skull, head and neck, lung, spine, pancreas, and pelvis with an evidence-based approach.<span style="mso-spacerun:yes;"> </span>The clinical experience will also include benign tumors as well as functional disorders (trigeminal neuralgia, essential/Parkinsonian tremors).<span style="mso-spacerun:yes;"> </span>Along with clinical training, the fellow will be able to obtain mastery of multiple SRS/SBRT platforms including Cyberknife™, Gamma Knife™, Trilogy™, and Synergy™.<span style="mso-spacerun:yes;"> </span>The ability to acquire training on the major radiosurgical platforms is a unique attribute of the program at the University of Pittsburgh.<span style="mso-spacerun:yes;"> </span>The research component of the training will be focused on: 1) grant proposals 2) development of prospective clinical and translational trials 3) assessment and reporting clinical outcomes from one of the largest clinical programs in the United States.<span style="mso-spacerun:yes;"> </span>The Department of Radiation Oncology at the UPCI has a robust research infrastructure and has contributed much to the body of literature, and so the fellow will be expected to continue and augment this. </span></p> <p style="margin:0in 0in 10pt 0.25in;text-indent:-0.25in;mso-list:l0 level1 lfo1;tab-stops:list .25in;" class="MsoNormal"><span style="font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;"><span style="mso-list:Ignore;"><span style="font-size:small;">·</span><span style="font:7pt 'Times New Roman';"> </span></span></span><span style="font-size:small;font-family:Calibri;">The fellowship director is Dwight E. Heron, M.D., FACRO: HerondD2@upmc.edu.</span></p> <p style="margin:0in 0in 10pt 0.25in;text-indent:-0.25in;mso-list:l0 level1 lfo1;tab-stops:list .25in;" class="MsoNormal"><span style="font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;"><span style="mso-list:Ignore;"><span style="font-size:small;">·</span><span style="font:7pt 'Times New Roman';"> </span></span></span><span style="font-size:small;font-family:Calibri;">The pre-requisite for the fellowship is successful completion of an ACGME accredited residency in Radiation Oncology by the start date of the fellowship (July-August 2010). All applications must be received by May 14<sup>th</sup>, 2010.</span></p> <p style="margin:0in 0in 10pt 0.25in;text-indent:-0.25in;mso-list:l0 level1 lfo1;tab-stops:list .25in;" class="MsoNormal"><span style="font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;"><span style="mso-list:Ignore;"><span style="font-size:small;">·</span><span style="font:7pt 'Times New Roman';"> </span></span></span><span style="font-size:small;font-family:Calibri;">The application must include a current Curriculum Vitae, a one page personal statement articulating the candidate’s interest in the radiosurgical fellowship, and 3 letters of recommendation from clinical and/or research mentors.</span></p> <p style="margin:0in 0in 10pt 0.25in;text-indent:-0.25in;mso-list:l0 level1 lfo1;tab-stops:list .25in;" class="MsoNormal"><span style="font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;"><span style="mso-list:Ignore;"><span style="font-size:small;">·</span><span style="font:7pt 'Times New Roman';"> </span></span></span><span style="font-size:small;font-family:Calibri;">Please e-mail CV and essay to Ms. Erica Franko: </span><a href="mailto:efranko@upmc.edu"><span style="font-size:small;font-family:Times New Roman;">efranko@upmc.edu</span></a><span style="font-size:small;font-family:Calibri;"> and have letters of recommendation sent to:</span></p> <p style="margin:0in 0in 0pt;line-height:normal;" class="MsoNormal"><span style="font-size:small;font-family:Calibri;">Erika Franko</span></p> <p style="margin:0in 0in 0pt;line-height:normal;" class="MsoNormal"><span style="font-size:small;font-family:Calibri;">UPCI Department of Radiation Oncology</span></p> <p style="margin:0in 0in 0pt;line-height:normal;" class="MsoNormal"><span style="font-size:small;font-family:Calibri;">UPMC Cancer Pavilion</span></p> <p style="margin:0in 0in 0pt;line-height:normal;" class="MsoNormal"><span style="font-size:small;font-family:Calibri;">5230 Centre Ave</span></p> <p style="margin:0in 0in 0pt;line-height:normal;" class="MsoNormal"><span style="font-size:small;font-family:Calibri;">#548</span></p> <p style="margin:0in 0in 0pt;line-height:normal;" class="MsoNormal"><span style="font-size:small;"><span style="font-family:Calibri;">Pittsburgh, PA 15232</span></span></p><div style="clear:both;"></div> </article> <article> <h1>Neuroblastoma</h1> <p>ARRO — Thu, 12 Nov 2009 19:54:53 GMT</p> <p>CCG 3881 <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Perez+CA%22%5BAuthor%5D" target="_blank"> Perez CA</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Matthay+KK%22%5BAuthor%5D" target="_blank"> Matthay KK</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Atkinson+JB%22%5BAuthor%5D" target="_blank"> Atkinson JB</a>, et al. <b>Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10623689&query_hl=10" target="_blank">J Clin Oncol. 2000 Jan;18(1):18-26.</a></p> <p> CCG 3891 Matthay KK, Villablanca JG, Seeger RC, et al. <b>Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10519894&query_hl=19" target="_blank">N Engl J Med. 1999 Oct 14;341(16):1165-73. </a></p><div style="clear:both;"></div> </article> <article> <h1>Prostate</h1> <p>ARRO — Thu, 12 Nov 2009 19:53:02 GMT</p> <h2><b>Dose Escalation</b></h2> <p>Pollack Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12128107&query_hl=36" target="_blank">Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105. </a></p> <p>PROG 95-09 <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Zietman+AL%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Zietman AL</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22DeSilvio+ML%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">DeSilvio ML</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Slater+JD%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Slater JD</a>, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16160131&query_hl=21" target="_blank">JAMA. 2005 Sep 14;294(10):1233-9.</a></p> <p>External Beam +/- Brachytherapy <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Sathya+JR%22%5BAuthor%5D" target="_blank"> Sathya JR</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Davis+IR%22%5BAuthor%5D" target="_blank"> Davis IR</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Julian+JA%22%5BAuthor%5D" target="_blank"> Julian JA</a>, et al. <b>Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. </b><b></b><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15718316" target="_blank">J Clin Oncol. 2005 Feb 20;23(6):1192-9.</a></p> <h2><b>Fields</b></h2> <p>RTOG 75-06 <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Pilepich+MV%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Pilepich MV</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Krall+JM%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Krall JM</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Johnson+RJ%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Johnson RJ</a>, et al. Extended field (periaortic) irradiation in carcinoma of the prostate--analysis of RTOG 75-06. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=3514555&query_hl=18" target="_blank">Int J Radiat Oncol Biol Phys. 1986 Mar;12(3):345-51.</a></p> <p>RTOG 77-06 <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Asbell+SO%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Asbell SO</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Krall+JM%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Krall JM</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Pilepich+MV%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Pilepich MV</a>, et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=3514555&query_hl=18" target="_blank">Int J Radiat Oncol Biol Phys. 1986 Mar;12(3):345-51.</a></p> <p>RTOG 94-13 Roach M 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12743142&query_hl=54" target="_blank">J Clin Oncol. 2003 May 15;21(10):1904-11.</a> UPDATE: Lawton C., DeSilvio M., Roach III M., et al. <b>An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only ( PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13.</b><a href="http://www.rtog.org/abstracts/ASTROreferences.html#Lawton" target="_blank">Proc Amer Soc Thera Rad Onc (ASTRO), Denver, CO, Int J Radiat Oncol Biol Phys, [63] (Suppl. 1), pg. S19, Abs. #32, 2005.</a></p> <h2><b>General/Miscellaneous</b></h2> <p>Paulson Paulson DF, Lin GH, Hinshaw W, et al. Radical surgery versus radiotherapy for adenocarcinoma of the prostate.<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=6811766&query_hl=28" target="_blank"> J Urol. 1982 Sep;128(3):502-4.</a> </p> <p>Partin Tables Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11744442&query_hl=42" target="_blank">Urology. 2001 Dec;58(6):843-8.</a></p> <p>EORTC 22911 <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Bolla+M%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Bolla M</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22van+Poppel+H%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">van Poppel H</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Collette+L%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Collette L</a>, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16099293&query_hl=36" target="_blank">Lancet. 2005 Aug 13-19;366(9485):572-8.</a></p> <h2><b>Hormones</b></h2> <p>D’Amico D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15315996&query_hl=45" target="_blank">JAMA. 2004 Aug 18;292(7):821-7. </a></p> <p>EORTC 22863/Bolla <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Bolla+M%22%5BAuthor%5D" target="_blank"> Bolla M</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Collette+L%22%5BAuthor%5D" target="_blank"> Collette L</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Blank+L%22%5BAuthor%5D" target="_blank"> Blank L</a>, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12126818&query_hl=10" target="_blank">Lancet. 2002 Jul 13;360(9327):103-6. </a></p> <p> RTOG 85-31 M. V. Pilepich, K. Winter, C. Lawton, et al. Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. <a href="http://www.asco.org/ac/1,1003,_12-002636-00_18-0023-00_19-00101094,00.asp" target="_blank">Proc Am Soc Clin Oncol 22: page 381, 2003 (abstr 1530)</a>. ALSO <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=9060541&dopt=Abstract" target="_blank">J Clin Oncol. 1997 Mar;15(3):1013-21. </a></p> <p> RTOG 86-10 <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Pilepich+MV%22%5BAuthor%5D" target="_blank"> Pilepich MV</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Winter+K%22%5BAuthor%5D" target="_blank"> Winter K</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22John+MJ%22%5BAuthor%5D" target="_blank"> John MJ</a>, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11483335&query_hl=16" target="_blank">Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52. </a></p> <p> RTOG 92-02 <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Hanks+GE%22%5BAuthor%5D" target="_blank"> Hanks GE</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Pajak+TF%22%5BAuthor%5D" target="_blank"> Pajak TF</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Porter+A%22%5BAuthor%5D" target="_blank"> Porter A</a>, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14581419&query_hl=18" target="_blank">J Clin Oncol. 2003 Nov 1;21(21):3972-8.</a> </p> <h2><b>Watchful Waiting </b></h2> <p>Holmberg Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12226148&query_hl=21" target="_blank">N Engl J Med. 2002 Sep 12;347(11):781-9.</a> UPDATE: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Bill%2DAxelson+A%22%5BAuthor%5D" target="_blank">Bill-Axelson A</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Holmberg+L%22%5BAuthor%5D" target="_blank"> Holmberg L</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Ruutu+M%22%5BAuthor%5D" target="_blank"> Ruutu M</a>, et al. <b>Radical prostatectomy versus watchful waiting in early prostate cancer. </b><b></b><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15888698&query_hl=3&itool=pubmed_docsum" target="_blank">N Engl J Med. 2005 May 12;352(19):1977-84. </a></p> <p> Johansson <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Johansson+JE%22%5BAuthor%5D" target="_blank"> Johansson JE</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Holmberg+L%22%5BAuthor%5D" target="_blank"> Holmberg L</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Johansson+S%22%5BAuthor%5D" target="_blank"> Johansson S</a>, et al. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9020270&query_hl=30" target="_blank">JAMA. 1997 Feb 12;277(6):467-71. </a></p><div style="clear:both;"></div> </article> <article> <h1>Pancreas</h1> <p>ARRO — Thu, 12 Nov 2009 19:53:57 GMT</p> <p>GITSG 9173 <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Kalser+MH%22%5BAuthor%5D" target="_blank"> Kalser MH</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Ellenberg+SS%22%5BAuthor%5D" target="_blank"> Ellenberg SS</a>. <b>Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=3567862&query_hl=40" target="_blank">Arch Surg. 1985 Aug;120(8):899-903. ALSO Cancer. 1987 Jun 15;59(12):2006-10.</a> </p> <p> GITSG 9273 <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Moertel+CG%22%5BAuthor%5D" target="_blank"> Moertel CG</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Frytak+S%22%5BAuthor%5D" target="_blank"> Frytak S</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Hahn+RG%22%5BAuthor%5D" target="_blank"> Hahn RG</a>, et al. <b>Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7284971&query_hl=34" target="_blank">Cancer. 1981 Oct 15;48(8):1705-10. </a></p> <p> EORTC 40891 <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Klinkenbijl+JH%22%5BAuthor%5D" target="_blank"> Klinkenbijl JH</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Jeekel+J%22%5BAuthor%5D" target="_blank"> Jeekel J</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Sahmoud+T%22%5BAuthor%5D" target="_blank"> Sahmoud T</a>, et al. <b>Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. </b><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10615932&query_hl=42" target="_blank">Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4. </a></p> <p> ESPAC 1 <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Neoptolemos+JP%22%5BAuthor%5D"> Neoptolemos JP</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Stocken+DD%22%5BAuthor%5D"> Stocken DD</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Friess+H%22%5BAuthor%5D"> Friess H</a>, et al. <b>A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15028824&query_hl=58" target="_blank">N Engl J Med. 2004 Mar 18;350(12):1200-10. </a></p><div style="clear:both;"></div> </article> <article> <h1>Metastases - Spinal Cord</h1> <p>ARRO — Thu, 12 Nov 2009 19:56:42 GMT</p> <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Patchell+RA%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Patchell RA</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Tibbs+PA%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Tibbs PA</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Regine+WF%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Regine WF</a>, et al. <b>Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16112300&query_hl=20" target="_blank">Lancet. 2005 Aug 20-26;366(9486):643-8.</a></p> <p>Cord Tolerance <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Ang+KK%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Ang KK</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Price+RE%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Price RE</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Stephens+LC%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Stephens LC</a>, et al. <b>The tolerance of primate spinal cord to re-irradiation.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8436524&query_hl=23" target="_blank"> Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):459-64.</a></p><div style="clear:both;"></div> </article> <article> <h1>July 2011 Start - PGY2 Radiation Onocology at UNMC</h1> <p>Enke14350 — Wed, 21 Apr 2010 23:38:27 GMT</p> <p>The University of Nebraska Medical Center in Omaha, Nebraska, has a PGY2 Radiation Oncology residency position available starting July 1, 2011. Interested candidates should submit a CV, personal statement, USMLE scores, evidence of PGY1 and three letters of recommendation. Files are not considered complete until each of these are received. Please send these requirements to our program coordinator <a href="mailto:JBraun@unmc.edu"><span style="color:#3366cc;">JBraun@unmc.edu</span></a>. We will begin interviews approximately June 1st. </p> <p>Ken Zhen, MD, Professor & Program Director</p><div style="clear:both;"></div> </article> <article> <h1>Hepatobiliary</h1> <p>ARRO — Thu, 12 Nov 2009 20:13:17 GMT</p> <p>Pitt <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Pitt+HA%22%5BAuthor%5D" target="_blank"> Pitt HA</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Nakeeb+A%22%5BAuthor%5D" target="_blank"> Nakeeb A</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Abrams+RA%22%5BAuthor%5D" target="_blank"> Abrams RA</a>, et al. <b>Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7794082&query_hl=24" target="_blank">Ann Surg. 1995 Jun;221(6):788-97; discussion 797-8.</a></p> <p> Alden <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Alden+ME%22%5BAuthor%5D" target="_blank"> Alden ME</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Waterman+FM%22%5BAuthor%5D" target="_blank"> Waterman FM</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Topham+AK%22%5BAuthor%5D" target="_blank"> Topham AK</a>, et al. <b>Cholangiocarcinoma: clinical significance of tumor location along the extrahepatic bile duct.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7480704&query_hl=35" target="_blank">Radiology. 1995 Nov;197(2):511-6. </a></p><div style="clear:both;"></div> </article> <article> <h1>Lung cancer</h1> <p>ARRO — Thu, 12 Nov 2009 20:01:52 GMT</p> <h2><b>Lung cancer - Miscellaneous </b></h2> <p>V20 <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Graham+MV%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Graham MV</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Purdy+JA%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Purdy JA</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Emami+B%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Emami B</a>, et al. <b>Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). </b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10487552&query_hl=18" target="_blank">Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):323-9.</a></p> <h2><b>Lung cancer - NSCLC – With chemotherapy </b></h2> <p> CALGB 8433 Dillman RO, Seagren SL, Propert KJ, et al. <b>A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2169587" target="_blank">NEJM 323(14):940-5, 1990. </a></p> <p> RTOG 9309/Intergroup 0139 K. S. Albain, R. S. Swann, V. R. Rusch, , et al. <b>Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309).</b> <a href="http://www.asco.org/ac/1,1003,_12-002636-00_18-0034-00_19-0030938,00.asp" target="_blank">Proc Am Soc Clin Oncol, abstract 7014, 2005. </a></p> <p>LAMP <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Belani+CP%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Belani CP</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Choy+H%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Choy H</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Bonomi+P%22%5BAuthor%5D" title="Click to search for citations by this author." target="_blank">Bonomi P</a>, et al. <b>Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16087941&query_hl=21" target="_blank">J Clin Oncol. 2005 Sep 1;23(25):5883-91. Epub 2005 Aug 8.</a></p> <p> RTOG 94-10 Curran WJ, Scott C, Langer C, et al. <b>Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lun cancer: initial report of Radiation Therapy Oncology Group 9410.</b> <a href="http://www.asco.org/ac/1,1003,_12-002636-00_18-0023-00_19-00102234,00.asp" target="_blank">Proc Am Soc Clin Oncol 22:abstract 2499, p 621, 2003. </a></p> <h2><b> Lung Cancer - NSCLC – Postop and Dose Escalation </b></h2> <p>Lung Cancer Study Group [No authors listed] <b>Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. The Lung Cancer Study Group.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2877397" target="_blank">NEJM 35(22):1377-81, 1986.</a> </p> <p> PORT Meta-analysis [No authors listed] <b>Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9690404" target="_blank">Lancet. 1998 Jul 25;352(9124):257-63.</a></p> <p> RTOG 73-01 Perez CA , Pajak TF, Rubin P, et al. <b>Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=3032394" target="_blank">Report by the Radiation Therapy Oncology Group (73-01). Cancer 59(11):1874-1881, 1987.</a> </p> <p> RTOG 83-11 Cox JD, Azarnia N, Byhardt RW, et al. <b>A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma</b>: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2167952" target="_blank">report of Radiation Therapy Oncology Group 83-11. JCO 8(9):1543-55, 1990. </a></p> <p> CHART <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Saunders+M%22%5BAuthor%5D"> Saunders M</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Dische+S%22%5BAuthor%5D"> Dische S</a>, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Barrett+A%22%5BAuthor%5D"> Barrett A</a>, et al. <b>Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. </b><b></b><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10577699&query_hl=4&itool=pubmed_docsum">Radiother Oncol. 1999 Aug;52(2):137-48.</a></p> <h2><b> Lung Cancer – Small Cell </b><b> </b></h2> <p> Intergroup 0096 Turrisi AT 3rd, Kim K, Blum R, et al. <b>Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9920950" target="_blank">N Engl J Med. 1999 Jan 28;340(4):265-71.</a> </p> <p> NCIC Murray N, Coy P, Pater JL, et al. <b>Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8381164" target="_blank">J Clin Oncol. 1993 Feb;11(2):336-44. </a></p> <p> Auperin Meta-analysis Auperin A, Arriagada R, Pignon JP, et al. <b>Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10441603" target="_blank">N Engl J Med. 1999 Aug 12;341(7):476-84. </a></p> <p> Pignon Meta-analysis Pignon JP, Arriagada R, Ihde DC, et al. <b>A meta-analysis of thoracic radiotherapy for small-cell lung cancer.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1331787" target="_blank">N Engl J Med. 1992 Dec 3;327(23):1618-24.</a></p> <p> Jeremic Jeremic B, Shibamoto Y, Nikolic N, et al. <b>Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10561263" target="_blank">J Clin Oncol. 1999 Jul;17(7):2092-9.</a></p><div style="clear:both;"></div> </article> <article> <h1>Lymphoma - Hodgkin’s</h1> <p>ARRO — Thu, 12 Nov 2009 20:08:03 GMT</p> <p>Milan Bonadonna G, Bonfante V, Viviani S, et al. <b>ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15199092" target="_blank">J Clin Oncol. 2004 Jul 15;22(14):2835-41. Epub 2004 Jun 15. </a></p> <p> German HD8 Engert A, Schiller P, Josting A, et al.<b> Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group</b>.<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12913100" target="_blank"> J Clin Oncol. 2003 Oct 1;21(19):3601-8. Epub 2003 Aug 11. </a></p> <p> CALGB Canellos GP, Anderson JR, Propert KJ, et al. <b>Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.</b> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1383821" target="_blank">N Engl J Med. 1992 Nov 19;327(21):1478-84. </a></p> <p> EORTC 20884 Aleman BM, Raemaekers JM, Tirelli U, et al. <b>Involved-field radiotherapy for advanced Hodgkin's lymphoma</b>. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12802025" target="_blank">N Engl J Med. 2003 Jun 12;348(24):2396-406. </a></p> <p> </p><div style="clear:both;"></div> </article> </main></body></html>